|Table of Contents|

Clinical research progress of BRCA1/2 mutation and homologous recombination deficiency (HRD) detection in breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 10
Page:
1940-1943
Research Field:
Publishing date:

Info

Title:
Clinical research progress of BRCA1/2 mutation and homologous recombination deficiency (HRD) detection in breast cancer
Author(s):
FENG Cong; ZHANG Yinbin; WU Fei; LI Jia; LI Chaofan; WANG Weiwei; ZHANG Shuqun
Department of Oncology,the Second Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710004,China.
Keywords:
breast cancer; BRCA1/2; homologous recombination deficiency; clinical research; PARP inhibitor
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.10.033
Abstract:
Breast cancer has become the most prevalent cancer,and DNA repair deficiency is one of the most important features of breast cancer.Previous studies have shown that breast cancer susceptibility gene 1/2 (BRCA1/2) mutations are the predominant biomarkers for predicting homologous recombination deficiency (HRD) in breast cancer because of the ability to identify the population that would benefit from platinum drugs and poly ADP ribose polymerase (PARP) inhibitors.The U.S.Food and Drug Administration (FDA) has approved Olaparib and Talazoparib,two PARP inhibitors,for the adjuvant treatment of early and advanced breast cancer with BRCA1/2 mutations.However,they have not yet been approved in China.Available studies suggest that a proportion of breast cancer patients with non-BRCA1/2 mutations also have HRD signatures and could benefit from platinum drugs or PARP inhibitors.This review summarizes the progress of clinical researches involving BRCA1/2 mutation,homologous recombination repair (HRR) gene mutation and HRD status detection.We elucidate the value of various assays in identifying HRD status and predicting efficacy in breast cancer patients,and suggest that HRD detection methods for breast cancer in China should be developed as soon as possible.

References:

［1］ ALI RMM,MCINTOSH SA,SAVAGE KI.Homologous recombination deficiency in breast cancer:Implications for risk,cancer development,and therapy ［J］.Genes Chromosomes Cancer,2021,60(5):358-372.
［2］ JACKSON SP,BARTEK J.The DNA-damage response in human biology and disease ［J］.Nature,2009,461(7267):1071-1078.
［3］ 陈锐,纪元,申鹏,等.同源重组修复缺陷临床检测与应用专家共识（2021版） ［J］.中国癌症防治杂志,2021,13(04):329-338. CHEN R,JI Y,SHEN P,et al.Expert consensus on clinical detection and application of homologous recombination repair deficiency (2021) ［J］.Chinese Journal Oncology Prevention and Treatment,2021,13(04):329-338.
［4］ DEN BROK WD,SCHRADER KA,SUN S,et al.Homologous recombination deficiency in breast cancer:a clinical review ［J］.JCO Precis Oncol,2017,1:1-13.
［5］ SUKUMAR J,GAST K,QUIROGA D,et al.Triple-negative breast cancer:promising prognostic biomarkers currently in development ［J］.Expert Rev Anticancer Ther,2021,21(2):135-148.
［6］ ROBSON M,IM SA,SENKUS E,et al.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation ［J］.N Engl J Med,2017,377(6):523-533.
［7］ LITTON JK,RUGO HS,ETTL J,et al.Talazoparib in patients with advanced breast cancer and a germline BRCA mutation ［J］.N Engl J Med,2018,379(8):753-763.
［8］ TUTT ANJ,GARBER JE,KAUFMAN B,et al.Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer ［J］.N Engl J Med,2021,384(25):2394-2405.
［9］ PATSOURIS A,DIOP K,TREDAN O,et al.Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency,without germline BRCA1/2 mutation ［J］.Eur J Cancer,2021,159:283-295.
［10］ GOU R,DONG H,LIN B.Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy ［J］.Life Sci,2020,261:118434.
［11］ SHERILL-ROFE D,RAHAT D,FINDLAY S,et al.Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes ［J］.Genome Res,2019,29(3):439-448.
［12］ ALEXANDROV LB,KIM J,HARADHVALA NJ,et al.The repertoire of mutational signatures in human cancer ［J］.Nature,2020,578(7793):94-101.
［13］ CRUZ C,CASTROVIEJO-BERMEJO M,GUTIERREZ-ENRIQUEZ S,et al.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer ［J］.Ann Oncol,2018,29(5):1203-1210.
［14］ ISAKOFF SJ,MAYER EL,HE L,et al.TBCRC009:A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer ［J］.J Clin Oncol,2015,33(17):1902-1909.
［15］ KAKLAMANI VG,JERUSS JS,HUGHES E,et al.Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579) ［J］.Breast Cancer Res Treat,2015,151(3):629-638.
［16］ LOIBL S,WEBER KE,TIMMS KM,et al.Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto ［J］.Ann Oncol,2018,29(12):2341-2347.
［17］ TELLI ML,JENSEN KC,VINAYAK S,et al.Phase II study of gemcitabine,carboplatin,and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability:PrECOG 0105 ［J］.J Clin Oncol,2015,33(17):1895-1901.
［18］ TELLI ML,TIMMS KM,REID J,et al.Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer ［J］.Clin Cancer Res,2016,22(15):3764-3773.
［19］ TUTT A,TOVEY H,CHEANG MCU,et al.Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups:the TNT trial ［J］.Nat Med,2018,24(5):628-637.
［20］ MAYER EL,ABRAMSON V,JANKOWITZ R,et al.TBCRC 030:a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer:evaluating the homologous recombination deficiency (HRD) biomarker ［J］.Ann Oncol,2020,31(11):1518-1525.
［21］ PANDY JGP,BALOLONG-GARCIA JC,CRUZ-ORDINARIO MVB,et al.Triple negative breast cancer and platinum-based systemic treatment:a meta-analysis and systematic review ［J］.BMC Cancer,2019,19(1):1065.
［22］ SHARMA P,RODLER E,BARLOW WE,et al.Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416) ［J］.Journal of Clinical Oncology,2020,38(15_suppl):1001.
［23］ FASCHING PA,LINK T,HAUKE J,et al.Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) ［J］.Ann Oncol,2021,32(1):49-57.
［24］ WOLF DM,YAU C,SANIL A,et al.DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial ［J］.NPJ Breast Cancer,2017,3:31.
［25］ LOIBL S,O'SHAUGHNESSY J,UNTCH M,et al.Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess):a randomised,phase 3 trial ［J］.Lancet Oncol,2018,19(4):497-509.
［26］ TUNG NM,ROBSON ME,VENTZ S,et al.TBCRC 048:Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes ［J］.J Clin Oncol,2020,38(36):4274-4282.
［27］ DAVIES H,GLODZIK D,MORGANELLA S,et al.HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures ［J］.Nat Med,2017,23(4):517-525.
［28］ NGUYEN L,J WMM,VAN HOECK A,et al.Pan-cancer landscape of homologous recombination deficiency ［J］.Nat Commun,2020,11(1):5584.
［29］ SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2022 ［J］.CA Cancer J Clin,2022,72(1):7-33.

Memo

Memo:
National Natural Science Foundation of China(No.82174164);国家自然科学基金资助项目（编号：82174164）
Last Update: 1900-01-01